<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reactivation, recurrence or <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV) represent severe complications of biological therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Reported is a case of a 58-year-old female treated in the past with <z:chebi fb="0" ids="35610">cytostatics</z:chebi> and rituximab for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in whom HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was detected during a follow-up of the contacts of her partner diagnosed with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> B </plain></SENT>
<SENT sid="2" pm="."><plain>At the beginning, the patient had a very high serum level of HBV DNA (4.3 Ã— 108 IU/mL) and therefore she was treated with combined antiviral therapy (lamivudine and tenofovir) </plain></SENT>
<SENT sid="3" pm="."><plain>After 10 months, the serum level of HBV DNA decreased significantly (3,100 IU/mL) and the combined antiviral therapy was switched to monotherapy with tenofovir </plain></SENT>
<SENT sid="4" pm="."><plain>Another 5 months later, the serum level of HBV DNA was only 950 IU/mL </plain></SENT>
<SENT sid="5" pm="."><plain>This case demonstrates important clinical problems connected with HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in immunocompromised persons </plain></SENT>
</text></document>